Detection of high-risk patients resistant to CDK4/6 inhibitors with hormone receptor-positive HER2-negative advanced and metastatic breast cancer in Japan (KBCSG-TR-1316)

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: 1 Online-Ressource.

Language: Englisch

Bibliographic citation: Detection of high-risk patients resistant to CDK4/6 inhibitors with hormone receptor-positive HER2-negative advanced and metastatic breast cancer in Japan (KBCSG-TR-1316) ; volume:30 ; number:6 ; day:24 ; month:7 ; year:2023 ; pages:943-951 ; date:11.2023
Breast cancer ; 30, Heft 6 (24.7.2023), 943-951, 11.2023

Creator: Futamura, Manabu
Nakayama, Takahiro
Yoshinami, Tetsuhiro
Oshiro, Chiya
Ishihara, Mikiya
Morita, Midori
Watanabe, Akira
Tanigichi, Azusa
Tsukabe, Masami
Shimoda, Masafumi
Nitta, Kanae
Chihara, Yoko
Yasojima, Hiroyuki
Ouchi, Yoshimi
Tokumaru, Yoshihisa
Masuda, Norikazu

Contributor: SpringerLink (Online service)

DOI: 10.1007/s12282-023-01485-y

URN: urn:nbn:de:101:1-2024010810085016144073

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:33 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Futamura, Manabu
Nakayama, Takahiro
Yoshinami, Tetsuhiro
Oshiro, Chiya
Ishihara, Mikiya
Morita, Midori
Watanabe, Akira
Tanigichi, Azusa
Tsukabe, Masami
Shimoda, Masafumi
Nitta, Kanae
Chihara, Yoko
Yasojima, Hiroyuki
Ouchi, Yoshimi
Tokumaru, Yoshihisa
Masuda, Norikazu
SpringerLink (Online service)

Other Objects (12)

Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer

Immunotherapy for hormone receptor‒positive HER2-negative breast cancer

Elderly patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors in a multicentre cohort

EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer

Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer

CDK4/6 inhibitors, PI3K/mTOR inhibitors, and HDAC inhibitors as second-line treatments for hormone receptor-positive, HER2-negative advanced breast cancer: a network meta-analysis

Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy

Prognostic impact of adjuvant endocrine therapy for estrogen receptor-positive and HER2-negative T1a/bN0M0 breast cancer

The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR + /HER2 −) advanced/metastatic breast cancer

Systemic therapy of premenopausal patients with early stage hormone receptor-positive, HER2-negative breast cancer – controversies and standards in healthcare

Systemic Therapy of Premenopausal Patients with Early Stage Hormone Receptor-Positive, HER2-Negative Breast Cancer – Controversies and Standards in Healthcare

Systemic therapy of premenopausal patients with early stage hormone receptor-positive, HER2-negative breast cancer: controversies and standards in healthcare

Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer

Immunotherapy for hormone receptor‒positive HER2-negative breast cancer

Elderly patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors in a multicentre cohort

EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer

Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer

CDK4/6 inhibitors, PI3K/mTOR inhibitors, and HDAC inhibitors as second-line treatments for hormone receptor-positive, HER2-negative advanced breast cancer: a network meta-analysis

Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy

Prognostic impact of adjuvant endocrine therapy for estrogen receptor-positive and HER2-negative T1a/bN0M0 breast cancer

The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR + /HER2 −) advanced/metastatic breast cancer

Systemic therapy of premenopausal patients with early stage hormone receptor-positive, HER2-negative breast cancer – controversies and standards in healthcare

Systemic Therapy of Premenopausal Patients with Early Stage Hormone Receptor-Positive, HER2-Negative Breast Cancer – Controversies and Standards in Healthcare

Systemic therapy of premenopausal patients with early stage hormone receptor-positive, HER2-negative breast cancer: controversies and standards in healthcare

Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer

Immunotherapy for hormone receptor‒positive HER2-negative breast cancer

Elderly patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors in a multicentre cohort

EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer

Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer

CDK4/6 inhibitors, PI3K/mTOR inhibitors, and HDAC inhibitors as second-line treatments for hormone receptor-positive, HER2-negative advanced breast cancer: a network meta-analysis

Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy

Prognostic impact of adjuvant endocrine therapy for estrogen receptor-positive and HER2-negative T1a/bN0M0 breast cancer

The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR + /HER2 −) advanced/metastatic breast cancer

Systemic therapy of premenopausal patients with early stage hormone receptor-positive, HER2-negative breast cancer – controversies and standards in healthcare

Systemic Therapy of Premenopausal Patients with Early Stage Hormone Receptor-Positive, HER2-Negative Breast Cancer – Controversies and Standards in Healthcare

Systemic therapy of premenopausal patients with early stage hormone receptor-positive, HER2-negative breast cancer: controversies and standards in healthcare

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Detection of high-risk patients resistant to CDK4/6 inhibitors with hormone receptor-positive HER2-negative advanced and metastatic breast cancer in Japan (KBCSG-TR-1316)

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer

Immunotherapy for hormone receptor‒positive HER2-negative breast cancer

Elderly patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors in a multicentre cohort

EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer

Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer

CDK4/6 inhibitors, PI3K/mTOR inhibitors, and HDAC inhibitors as second-line treatments for hormone receptor-positive, HER2-negative advanced breast cancer: a network meta-analysis

Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy

Prognostic impact of adjuvant endocrine therapy for estrogen receptor-positive and HER2-negative T1a/bN0M0 breast cancer

The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR + /HER2 −) advanced/metastatic breast cancer

Systemic therapy of premenopausal patients with early stage hormone receptor-positive, HER2-negative breast cancer – controversies and standards in healthcare

Systemic Therapy of Premenopausal Patients with Early Stage Hormone Receptor-Positive, HER2-Negative Breast Cancer – Controversies and Standards in Healthcare

Systemic therapy of premenopausal patients with early stage hormone receptor-positive, HER2-negative breast cancer: controversies and standards in healthcare

Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer

Immunotherapy for hormone receptor‒positive HER2-negative breast cancer

Elderly patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors in a multicentre cohort

EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer

Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer

CDK4/6 inhibitors, PI3K/mTOR inhibitors, and HDAC inhibitors as second-line treatments for hormone receptor-positive, HER2-negative advanced breast cancer: a network meta-analysis

Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy

Prognostic impact of adjuvant endocrine therapy for estrogen receptor-positive and HER2-negative T1a/bN0M0 breast cancer

The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR + /HER2 −) advanced/metastatic breast cancer

Systemic therapy of premenopausal patients with early stage hormone receptor-positive, HER2-negative breast cancer – controversies and standards in healthcare

Systemic Therapy of Premenopausal Patients with Early Stage Hormone Receptor-Positive, HER2-Negative Breast Cancer – Controversies and Standards in Healthcare

Systemic therapy of premenopausal patients with early stage hormone receptor-positive, HER2-negative breast cancer: controversies and standards in healthcare

Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer

Immunotherapy for hormone receptor‒positive HER2-negative breast cancer

Elderly patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors in a multicentre cohort

EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer

Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer

CDK4/6 inhibitors, PI3K/mTOR inhibitors, and HDAC inhibitors as second-line treatments for hormone receptor-positive, HER2-negative advanced breast cancer: a network meta-analysis

Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy

Prognostic impact of adjuvant endocrine therapy for estrogen receptor-positive and HER2-negative T1a/bN0M0 breast cancer

The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR + /HER2 −) advanced/metastatic breast cancer

Systemic therapy of premenopausal patients with early stage hormone receptor-positive, HER2-negative breast cancer – controversies and standards in healthcare

Systemic Therapy of Premenopausal Patients with Early Stage Hormone Receptor-Positive, HER2-Negative Breast Cancer – Controversies and Standards in Healthcare

Systemic therapy of premenopausal patients with early stage hormone receptor-positive, HER2-negative breast cancer: controversies and standards in healthcare

Related objects

Reset password